Dier Mardi's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Mar 3, 2022
- Accession no.
- 0001209191-22-015833
- Filed
- Mar 3, 2022
- Trade date
- Mar 1-3, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $62.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dier MardiCIK 0001574591 | Officer (CFO & Executive Vice President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Common Stock | SSaleDisposed | −534 | $66.62 | −$35,575.08 | 38,228 | Direct | |
| Mar 1, 2022 | Common Stock | AGrant or awardAcquired | +14,000 | $0.00 | $0 | 52,228 | Direct | |
| Mar 3, 2022 | Common Stock | SSaleDisposed | −420 | $64.55 | −$27,111 | 51,808 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Common Stock | AGrant or awardAcquired | +24,900 | $0.00 | $0 | 24,900 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.